# EDGAR Filing Document

**Accession Number:** 0001278386
**File Stem:** 0001213900-26-005310
**Filing Date:** 2026-1
**Character Count:** 54270
**Document Hash:** 732a69e9a4b3b7c5d746b890b8d1ed93
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-26-005310.hdr.sgml**: 20260116

**ACCESSION NUMBER**: 0001213900-26-005310

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 4

**FILED AS OF DATE**: 20260116

**DATE AS OF CHANGE**: 20260116

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** STAAR SURGICAL CO
- **CENTRAL INDEX KEY:** 0000718937
- **STANDARD INDUSTRIAL CLASSIFICATION:** OPHTHALMIC GOODS [3851]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 953797439
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1227

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-36017
- **FILM NUMBER:** 26540833

**BUSINESS ADDRESS:**
- **STREET 1:** 1911 WALKER AVE
- **CITY:** MONROVIA
- **STATE:** CA
- **ZIP:** 91016
- **BUSINESS PHONE:** 6263037902

**MAIL ADDRESS:**
- **STREET 1:** 1911 WALKER AVE
- **CITY:** MONROVIA
- **STATE:** CA
- **ZIP:** 91016

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** STAAR SURGICAL COMPANY
- **DATE OF NAME CHANGE:** 19920703
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BROADWOOD PARTNERS, L.P.
- **CENTRAL INDEX KEY:** 0001278386

**ORGANIZATION NAME:**
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**BUSINESS ADDRESS:**
- **STREET 1:** BROADWOOD CAPITAL INC.
- **STREET 2:** 156 WEST 56TH STREET, 3RD FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10019
- **BUSINESS PHONE:** 212-508-5735

**MAIL ADDRESS:**
- **STREET 1:** BROADWOOD CAPITAL INC.
- **STREET 2:** 156 WEST 56TH STREET, 3RD FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10019

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** BROADWOOD PARTNERS LP
- **DATE OF NAME CHANGE:** 20040202

## Exhibit 99.1

**Exhibit 99.1**

January 14, 2026

Broadwood Partners, L.P.<br> c/o Broadwood Capital, Inc.<br> 156 West 56th Street, 3rd Floor<br> New York, New York 10019

**Re: STAAR Surgical Company**

Dear Mr. Bradsher:

This letter agreement (this "**Agreement**"), effective as of January 14, 2026 (the "**Effective Date**"), is intended to memorialize the understandings and agreements that have been reached between STAAR Surgical Company (the "**Company**") and Broadwood Partners, L.P. (collectively with its Affiliates (as defined below), "**Broadwood**") regarding compositional changes to the board of directors of the Company (the "**Board**") and certain other matters, as provided in this Agreement. The Company and Broadwood are together referred to herein as the "**Parties**," and each of the Company and Broadwood, respectively, a "**Party**."

In consideration of the promises, representations and mutual covenants and agreements set forth herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1. **<u>Board Composition Changes.</u>**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a. On the Effective Date, the Board, and all applicable committees of the Board, shall take all necessary
actions to: (i) accept the resignations of Stephen C. Farrell and Elizabeth Yeu from the Board; (ii) increase the size of the Board from
six to seven directors; and (iii) appoint Neal C. Bradsher, Christopher Min Fang Wang and Richard T. LeBuhn (each, a "**New Director**") to the Board in order to fill the newly created vacancies resulting from the increased size of the Board and the
resignations of Mr. Farrell and Ms. Yeu. Mr. Farrell will also resign or retire as CEO of the Company as of January 31, 2026 or at an
earlier time determined by the Board.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b. The Board, and all applicable committees of the Board, shall take all necessary actions to nominate each
New Director as a candidate for election to the Board at the Company's 2026 annual meeting of stockholders (including, without limitation,
any adjournments or postponements thereof and any meeting which may be called in lieu thereof, the "**2026 Annual Meeting** ").
The Company shall recommend, support and solicit proxies for the election of each New Director at the 2026 Annual Meeting in a manner
no less rigorous and favorable than the manner in which the Company supports the Board's other nominees.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c. From the Effective Date until the conclusion of the Company's 2027 annual meeting of stockholders
(including, without limitation, any adjournments or postponements thereof and any meeting which may be called in lieu thereof), the size
of the Board shall not exceed seven directors.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. **<u>No Special Meeting.</u>** From the Effective Date until the first anniversary of the 2025 annual meeting of stockholders (June 18, 2026), Broadwood agrees that it and its Affiliates shall not, nor shall it encourage any other person to, request that the Company call a special meeting of the Company's stockholders for any reason.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. **<u>Mutual Non-Disparagement</u>**. Except for such truthful statements as may be required by applicable law or the rules of any self-regulatory organization, neither Party shall, nor shall it permit any of its Representatives to, directly or indirectly, in any capacity or manner, make, transmit or otherwise communicate any public statement of any kind, whether verbal, in writing, electronically transferred or otherwise, including, without limitation, to any member of the media, that constitutes an *ad hominem* attack on, or otherwise disparages or defames the other Party (including, without limitation, in each case, its current and former directors, officers, employees and Affiliates). "**Representatives**" means (a) a person's Affiliates and Associates (each as defined in Rule 12b-2 of the Securities Exchange Act of 1934, as amended) and (b) its and their respective directors, officers, employees, partners, members, managers, consultants, legal or other advisors, agents and other representatives acting in a capacity on behalf of, in concert with or at the direction of such person or its Affiliates or Associates; <u>provided</u>, that when used with respect to the Company, "**Representatives**" shall not include any non-executive employees.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**4. <u>Mutual Liability Releases.</u>**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a. As of the Effective Date, the Company permanently, fully and completely releases, acquits and discharges
Broadwood and Broadwood's Affiliates and Associates (including, without limitation, in each case its current directors, officers
and employees), jointly or severally, of and from any and all claims, demands, damages, causes of action, debts, liabilities, controversies,
judgments and suits of every kind and nature whatsoever, foreseen, unforeseen, known or unknown, that the Company has had, now has, or
may have against any of Broadwood and/or Broadwood's Affiliates or Associates (including, without limitation, in each case its current
directors, officers and employees), collectively, jointly or severally, based on any facts, developments or circumstances existing at
any time prior to and including the Effective Date, including, without limitation, any and all such claims arising out of or in any way
whatsoever related to Broadwood's involvement with the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b. As of the Effective Date, Broadwood (on
 behalf of itself and each of its Affiliates) permanently, fully and completely releases,
 acquits and discharges the Company and the Company's Affiliates and Associates (including,
 without limitation, in each case its current directors, officers and employees), jointly
 or severally, of and from any and all claims, demands, damages, causes of action, debts,
 liabilities, controversies, judgments and suits of every kind and nature whatsoever, foreseen,
 unforeseen, known or unknown, that Broadwood has had, now has, or may have against any of
 the Company and/or the Company's Affiliates or Associates (including, without limitation,
 in each case its current directors, officers and employees), collectively, jointly or severally,
 based on any facts, developments or circumstances existing at any time prior to and including
 the Effective Date, including, without limitation, any and all such claims arising out of
 or in any way whatsoever related Broadwood's or its Affiliates' involvement with
 the Company.<sup>1</sup>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c. The Parties each acknowledge that as of the time of the Effective Date, the Parties may have claims
against one another that a Party does not know or suspect to exist in its favor, including, but not limited to, claims that, had they
been known, might have affected the decision to enter into this Agreement, or to provide the releases set forth in this <u>Section 4</u>.
In connection with any such claims, the Parties agree that they intend to waive, relinquish and release any and all provisions, rights
and benefits in any state or territory of the United States or other jurisdiction that purports to limit the application of a release
to unknown claims, or to facts unknown at the time the release was entered into. In connection with this waiver, the Parties acknowledge
that they, or any of them, may (including, without limitation, after the Effective Date) discover facts in addition to or different from
those known or believed by them to be true with respect to the subject matter of the releases set forth in this <u>Section 4</u>,
but it is the intention of the Parties to complete, fully, finally and forever compromise, settle, release, discharge and extinguish any
and all claims that they may have one against another, known or unknown, suspected or unsuspected, contingent or absolute, accrued or
unaccrued, apparent or unapparent, that now exist or previously existed, without regard to the subsequent discovery of additional or different
facts. The Parties acknowledge that the foregoing waiver is a key, bargained-for element to this Agreement and the releases that are part
of it.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5. **<u>Mutually Agreed-Upon Press Release.</u>** Promptly following the Effective Date, the Company shall issue a press release (the "**Press Release**"), in the form attached hereto as <u>Exhibit A</u>, announcing, among other things, certain terms of this Agreement. Neither the Company nor Broadwood shall make or cause to be made, and the Company and Broadwood shall cause their respective Affiliates and Associates not to make or cause to be made, any public announcement or statement with respect to the subject matter of this Agreement that is contrary to the statements made in the Press Release or the terms of this Agreement without prior written consent of the other Party, except to the extent required by law or the rules of any national securities exchange.

<sup>1</sup> The release does not extend to claims Broadwood or its Affiliates may have as a passive member of a shareholder class action lawsuit, provided that Broadwood and its Affiliates do not solicit, knowingly encourage, promote, assist or otherwise support such class action lawsuit.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6. **<u>SEC Filings.</u>** No later than four business days following the execution of this Agreement, the Company shall file with the U.S. Securities and Exchange Commission (the "**SEC**") a Current Report on Form 8-K reporting its entry into this Agreement and appending this Agreement as an exhibit thereto. No later than two business days following the execution of this Agreement, Broadwood shall file with the SEC an amendment to its Schedule 13D reporting its entry into this Agreement and appending this Agreement as an exhibit thereto. Each Party shall provide the other Party with a reasonable opportunity to review and comment on its applicable SEC filing prior to such respective report or schedule being filed and consider in good faith any comments of the other Party.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**7. <u>Reimbursement of Expenses.</u>**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a. The Company shall promptly reimburse Broadwood for its reasonable and documented out-of-pocket fees and
expenses (including legal expenses) incurred by Broadwood in connection with its engagement with the Company, including, without limitation,
the special meeting of stockholders of the Company originally scheduled for October 23, 2025 and postponed and held on January 6, 2026
(the "**Proposed Merger Special Meeting** "), the negotiation and execution of this Agreement and the transactions
contemplated hereby; provided that the Company shall not be required to reimburse Broadwood for an aggregate amount in excess of $6 million.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b. The Company agrees that it will agree to reimburse each of Yunqi Capital and Defender Capital for expenses
it reasonably incurred in connection with the Proposed Merger Special Meeting; provided that the Company shall not be required to reimburse
Yunqi Capital and Defender Capital for an aggregate amount in excess of $1 million in the case of Yunqi Capital and $25,000 in the case
of Defender Capital.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8. **<u>Miscellaneous.</u>**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a. Any Party (the "**Non-Breaching Party**") may terminate this Agreement if the other Party
commits a breach of this Agreement (the "**Breaching Party**") that is not cured within fifteen calendar days after the
Breaching Party's receipt of written notice from the Non-Breaching Party or, if impossible to cure within fifteen calendar days,
which the Breaching Party has not taken any substantive action to cure within such fifteen-day period. Notwithstanding anything to the
contrary herein, Section 4 shall survive any termination of this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b. Each Party acknowledges and agrees that irreparable harm to the other Party may occur in the event any
of the provisions of this Agreement are not performed in accordance with their specific terms or are otherwise breached and that such
injury would not be adequately compensable by the remedies available at law (including, without limitation, the payment of money damages).
Accordingly, each Party will be entitled to specifically enforce the covenants and other agreements of the other Party contained in this
Agreement and to obtain injunctive relief restraining the other Party from breaching or threatening to breach this Agreement, and the
other Party will not take action, directly or indirectly, in opposition to the Party seeking such relief on the grounds that any other
remedy or relief is available at law or in equity. The Parties further agree to waive any requirement for the security or posting of any
bond in connection with any such relief. The prevailing Party that obtains a final, non-appealable order shall be entitled to recover
its fees and expenses incurred with respect to any action from the non-prevailing Party. The remedies available pursuant to this <u>Section 8(b)</u> shall not be deemed to be the exclusive remedies for a breach of this Agreement but shall be in addition to all other remedies available
at law or equity.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c. Each Party represents and warrants that it is duly authorized and has legal capacity to execute and deliver
this Agreement. Each Party represents and warrants to the other Parties that the execution and delivery of this Agreement and the performance
of such Party's obligations hereunder have been duly authorized and that this Agreement is a valid and legal agreement binding on
such Party and enforceable in accordance with its terms.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d. Any notices required or permitted to be given under this Agreement shall be in writing and shall be delivered
by overnight courier or electronic mail with confirmation of receipt to the addresses specified on the signature page of this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;e. This Agreement may be executed in one or more counterparts, each of which shall be deemed an original,
but all of which together shall constitute one and the same agreement. Signatures to this Agreement transmitted by electronic mail shall
have the same effect as physical delivery of the paper document bearing the original signature. No modifications of this Agreement can
be made except in writing signed by each of the Parties.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;f. If any provision of this Agreement is held invalid or unenforceable by any court of competent jurisdiction,
the other provisions shall remain in full force and effect and shall in no way be affected, impaired or invalidated. Any provision held
invalid or unenforceable only in part or degree shall remain in full force and effect to the extent not held invalid or unenforceable.
The Parties further agree to replace such invalid or unenforceable provision with a valid and enforceable provision that will achieve,
to the extent possible, the purposes of such invalid or unenforceable provision.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;g. This Agreement and all disputes or controversies out of or related to this Agreement shall be deemed to
be made under the laws of the State of Delaware and for all purposes shall be governed by, and construed in accordance with, the laws
of such State applicable to contracts to be made and performed entirely within such State, without reference to conflicts of laws principles.

 

*(Signature Pages Follow)*

If the foregoing accurately sets forth our agreements, please sign this Agreement where indicated below.

Sincerely,

**STAAR SURGICAL COMPANY**

---

| | | |
|:---|:---|:---|
| By: | /s/ Stephen C. Farrell | /s/ Stephen C. Farrell |
|  | Name: | Stephen C. Farrell |
|  | Title: | Chief Executive Officer |

---

Address for Notices for the Company:

STAAR Surgical Company

Attn: Nathaniel Sisitsky

25510 Commercentre Dr.

Lake Forest, California 92630

Email: nsisitsky@staar.com

ACKNOWLEDGED AND AGREED:

**BROADWOOD PARTNERS, L.P.**

By: Broadwood Capital, Inc., its general partner

---

| | | |
|:---|:---|:---|
| By: | /s/ Neal C. Bradsher | /s/ Neal C. Bradsher |
|  | Name: | Neal C. Bradsher |
|  | Title: | President of Broadwood Capital, Inc. |

---

<u>Address for Notices for Broadwood</u>:

Broadwood Partners, L.P.

c/o Broadwood Capital, Inc.

Attn: Neal C. Bradsher

156 West 56th Street, 3rd Floor

New York, New York 10019

Email: neal@broadwoodcapital.com

**Exhibit A**

**STAAR Surgical and Broadwood Partners Enter Into Cooperation Agreement**

***Neal Bradsher and Richard LeBuhn of Broadwood and Christopher Wang of Yunqi Capital have Joined STAAR Board***

***STAAR Chair Elizabeth Yeu and CEO Stephen Farrell have Stepped Down from the Board***

***Farrell will Remain CEO until January 31, 2026***

Lake Forest, CA - (BUSINESS WIRE) - STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer<sup>®</sup> Lenses (EVO ICL<sup>™</sup>) for vision correction, and Broadwood Partners, L.P. and its affiliates ("Broadwood"), which together own 31% of STAAR's outstanding common stock, today announced that Neal C. Bradsher and Richard T. LeBuhn of Broadwood and Christopher Wang of Yunqi Capital, which with its affiliates owns 6.5% of STAAR's outstanding common stock, have joined STAAR's Board of Directors (the "Board"), effective immediately.

These changes were made in connection with a cooperation agreement entered into between the Company and Broadwood (the "Cooperation Agreement"). As part of the Cooperation Agreement, STAAR Chair Elizabeth Yeu and CEO Stephen Farrell have stepped down as members of the Board, while Mr. Farrell will remain CEO until January 31, 2026. The STAAR Board has expanded its size from six members to seven. The renewed Board intends to make additional announcements regarding STAAR's next Chair and CEO in the near term.

STAAR director Louis Silverman said:

"We welcome our new Board members, who bring to STAAR expertise with respect to relevant public market investments, healthcare, and business in China, as well as the perspectives of long-term investors and supporters of STAAR. We will work together to enhance profitability and drive sustainable, long-term value creation. We are grateful to Liz and Steve for their service on STAAR's Board, and we appreciate Steve's leadership as CEO. We wish them both well."

Neal C. Bradsher, Broadwood Founder and President, said:

"I am honored to join STAAR's Board. The Company's leading technology, strong financial position, and privileged market position provide it with the opportunity to achieve growth and profit margin expansion. As STAAR's largest shareholder, Broadwood is committed to helping the Company realize its full potential. I want to thank Liz Yeu for her early recognition of the advantages of the ICL over tissue removal refractive procedures. I want to thank Steve Farrell for leading STAAR out of a difficult situation in early 2025 and back to profitability and cash flow generation. And I look forward to working with Art Butcher, an accomplished senior executive of one of the world's most successful medical device companies, as well as my other new colleagues on the STAAR Board. I believe that the exit compensation package provided to Steve by the prior board was appropriate based on the conditions at the time."

Broadwood has agreed to certain customary standstill provisions in connection with the Cooperation Agreement. The Cooperation Agreement will be filed by the Company with the U.S. Securities and Exchange Commission as an exhibit to the Current Report on Form 8-K.

**About Neal C. Bradsher**

Mr. Bradsher has been Founder and President of Broadwood Capital, Inc., a private investment firm, since 2002. Broadwood Capital, Inc. is the general partner of Broadwood Partners, L.P., which is currently the Company's largest stockholder. Mr. Bradsher holds a B.A. degree in economics from Yale College and is a Chartered Financial Analyst. Mr. Bradsher is currently a director at Lineage Cell Therapeutics, Inc., and served as a director of Questcor Pharmaceuticals, Inc. (QCOR), from 2004 until Questcor was acquired in 2014.

**About Richard T. LeBuhn**

Mr. LeBuhn serves as Executive Vice President at Broadwood Capital, Inc. Previously, Mr. LeBuhn was Principal of Broadfield Capital Management, LLC., and Vice President of Derchin Management. Mr. LeBuhn previously served as a director on the boards of Asterias Biotherapeutics, Inc. and Comarco, Inc. Mr. LeBuhn received a M.B.A. in Finance with Distinction from Columbia University Graduate School of Business. He received a B.A. in Economics from St. Lawrence University.

**About Christopher M. Wang**

Mr. Wang is the founder and CIO of Yunqi Capital. Prior to forming Yunqi Capital, Mr. Wang worked as a senior investment professional for Owl Creek Asset Management at the long/short equity hedge fund Owl Creek Asia based in Hong Kong from 2008 to 2017. Mr. Wang started his career as a senior analyst and was promoted to Assistant Portfolio Manager in 2013 and then to Co-Portfolio Manager in 2015. In the capacity of both Assistant Portfolio Manager and Co-Portfolio Manager, Mr. Wang was responsible for all aspects of the investment process. From 2004 to 2007, Mr. Wang was the General Manager, Corporate Finance Department of China Merchants (Holdings) International Ltd.

**About STAAR Surgical**

STAAR Surgical (NASDAQ: STAA) is the global leader in implantable phakic intraocular lenses, a vision correction solution that reduces or eliminates the need for glasses or contact lenses. Since 1982, STAAR has been dedicated solely to ophthalmic surgery, and for 30 years, STAAR has been designing, developing, manufacturing, and marketing advanced Implantable Collamer<sup>®</sup> Lenses (ICLs), using its proprietary biocompatible Collamer material. STAAR ICL's are clinically proven to deliver safe long-term vision correction without removing corneal tissue or the eye's natural crystalline lens. Its EVO ICL<sup>™</sup> product line provides visual freedom through a quick, minimally invasive procedure. STAAR has sold more than 3 million ICLs in over 75 countries. Headquartered in Lake Forest, California, the company operates research, development, manufacturing, and packaging facilities in California and Switzerland. For more information about ICL, visit <u>www.EVOICL.com</u>. To learn more about STAAR, visit <u>www.staar.com</u>.

**About Broadwood**

Broadwood Partners, L.P. is managed by Broadwood Capital, Inc. Broadwood Capital is a private investment firm based in New York City. Neal Bradsher is the President of Broadwood Capital.

**About Yunqi Capital**

Yunqi Capital is a Hong Kong headquartered investment manager with over US$250 million in assets under management. The firm deploys a fundamental long-short equity strategy, with a concentrated portfolio, that is primarily invested in the equity securities of companies with a significant China connection. Yunqi Capital is led by CIO Chris Wang, an experienced portfolio manager with a strong track record of generating attractive returns on capital, controlling portfolio risk and managing investment teams.

**Media Contact:**

Connie Johnson

<u>cjohnson@staar.com</u>

(626) 303-7902 (ext. 2207)

## Exhibit 99.2

**Exhibit 99.2**

**TRANSACTIONS IN ISSUER SECURITIES DURING THE PAST SIXTY (60) DAYS**

**BROADWOOD PARTNERS, L.P.**

---

| | | | |
|:---|:---|:---|:---|
| **Transaction Date** | **Nature of Transaction** | **Price Per Share** | **Quantity** |
| &nbsp;&nbsp;11/19/25 | &nbsp;&nbsp;Open Market Purchase | $26.4164<sup>1</sup> | 309132 |
| &nbsp;&nbsp;11/20/25 | &nbsp;&nbsp;Open Market Purchase | $27.1373<sup>2</sup> | 393382 |
| &nbsp;&nbsp;11/21/25 | &nbsp;&nbsp;Open Market Purchase | $27.8611<sup>3</sup> | 797486 |
| &nbsp;&nbsp;01/06/26 | &nbsp;&nbsp;Open Market Purchase | $21.0111<sup>4</sup> | 186946 |
| &nbsp;&nbsp;01/06/26 | &nbsp;&nbsp;Open Market Purchase | $22.3756<sup>5</sup> | 150000 |
| &nbsp;&nbsp;01/07/26 | &nbsp;&nbsp;Open Market Purchase | $22.0004<sup>6</sup> | 66467 |
| &nbsp;&nbsp;01/08/26 | &nbsp;&nbsp;Open Market Purchase | $21.9389<sup>7</sup> | 3240 |
| &nbsp;&nbsp;01/09/26 | &nbsp;&nbsp;Open Market Purchase | $22.0534<sup>8</sup> | 27485 |

---

<sup>1</sup> This constitutes the weighted average purchase price. The prices range from $25.60 to $26.50. The Reporting Person will provide upon request by the Securities and Exchange Commission staff (the "SEC Staff"), the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

<sup>2</sup> This constitutes the weighted average purchase price. The prices range from $26.56 to $27.35. The Reporting Person will provide upon request by the SEC Staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

<sup>3</sup> This constitutes the weighted average purchase price. The prices range from $27.30 to $28.23. The Reporting Person will provide upon request by the SEC Staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

<sup>4</sup> This constitutes the weighted average purchase price. The prices range from $20.92 to $21.09. The Reporting Person will provide upon request by the SEC Staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

<sup>5</sup> This constitutes the weighted average purchase price. The prices range from $21.97 to $22.58. The Reporting Person will provide upon request by the SEC Staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

<sup>6</sup> This constitutes the weighted average purchase price. The prices range from $21.81 to $22.09. The Reporting Person will provide upon request by the SEC Staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

<sup>7</sup> This constitutes the weighted average purchase price. The prices range from $21.86 to $21.97. The Reporting Person will provide upon request by the SEC Staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

<sup>8</sup> This constitutes the weighted average purchase price. The prices range from $21.965 to $22.09. The Reporting Person will provide upon request by the SEC Staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

## Exhibit 99.3

**Exhibit 99.3**

<u>JOINT FILING AGREEMENT</u>

In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, each of the undersigned agree to the joint filing on behalf of each of them of statements on Schedule 13D (including any amendments thereto), with respect to the common stock, par value $0.01 per share, of STAAR Surgical Company.

DATE: January 16, 2026

---

| | |
|:---|:---|
| BROADWOOD PARTNERS, L.P. | BROADWOOD PARTNERS, L.P. |
| By: | /s/ Neal C. Bradsher |
| Name: | Neal C. Bradsher |
| Title: | President of Broadwood Capital, Inc. |
| BROADWOOD CAPITAL, INC. | BROADWOOD CAPITAL, INC. |
| By: | /s/ Neal C. Bradsher |
| Name: | Neal C. Bradsher |
| Title: | President |
| NEAL C. BRADSHER | NEAL C. BRADSHER |
| /s/ Neal C. Bradsher | /s/ Neal C. Bradsher |
| RICHARD T. LEBUHN | RICHARD T. LEBUHN |
| /s/ Richard T. Lebuhn | /s/ Richard T. Lebuhn |

---

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 43)**

**STAAR SURGICAL CO**

*(Name of Issuer)*

**Common Stock, par value $0.01 per share**

*(Title of Class of Securities)*

**852312305**

*(CUSIP Number)*

**Neal C. Bradsher**<br>c/o Broadwood Capital, Inc.<br>156 West 56th Street, 3rd Floor,<br>New York NY 10019<br>(212) 508-5735

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**01/14/2026**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **852312305** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Broadwood Partners, L.P.** | Name of reporting person<br>**Broadwood Partners, L.P.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**15453629.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**15453629.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**15453629.00** | Aggregate amount beneficially owned by each reporting person<br>**15453629.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**31.1%** | Percent of class represented by amount in Row (11)<br>**31.1%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**PN** | Type of Reporting Person (See Instructions)<br>**PN** | |

---

| **CUSIP No.** | **852312305** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Broadwood Capital, Inc.** | Name of reporting person<br>**Broadwood Capital, Inc.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**NEW YORK** | Citizenship or place of organization<br>**NEW YORK** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**15453629.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**115453629.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**15453629.00** | Aggregate amount beneficially owned by each reporting person<br>**15453629.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**31.1%** | Percent of class represented by amount in Row (11)<br>**31.1%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**CO** | Type of Reporting Person (See Instructions)<br>**CO** | |

---

| **CUSIP No.** | **852312305** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Neal C. Bradsher** | Name of reporting person<br>**Neal C. Bradsher** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X1** | Citizenship or place of organization<br>**X1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**25900.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**15453629.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**25900.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**15453629.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**15479529.00** | Aggregate amount beneficially owned by each reporting person<br>**15479529.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**31.1%** | Percent of class represented by amount in Row (11)<br>**31.1%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

| **CUSIP No.** | **852312305** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Richard T. LeBuhn** | Name of reporting person<br>**Richard T. LeBuhn** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**PF** | Source of funds (See Instructions)<br>**PF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X1** | Citizenship or place of organization<br>**X1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**21280.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**6.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**21280.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**6.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**21286.00** | Aggregate amount beneficially owned by each reporting person<br>**21286.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[x] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[x] | |
| 13 | Percent of class represented by amount in Row (11)<br>**0.0%** | Percent of class represented by amount in Row (11)<br>**0.0%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Comment for Reporting Person:** Box 11 - Does not include 2,532 Shares over which Mr. LeBuhn does not have direct or indirect beneficial ownership. Such shares are held in three separate irrevocable trusts for Mr. LeBuhn's daughters in which Mr. LeBuhn has no voting or dispositive power and disclaims any beneficial ownership interest in such shares.

| **CUSIP No.** | **852312305** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Natalie R. Capasso** | Name of reporting person<br>**Natalie R. Capasso** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**—** | Source of funds (See Instructions)<br>**—** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X1** | Citizenship or place of organization<br>**X1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**0.00** | Aggregate amount beneficially owned by each reporting person<br>**0.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**0%** | Percent of class represented by amount in Row (11)<br>**0%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

| **CUSIP No.** | **852312305** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Raymond A. Myers** | Name of reporting person<br>**Raymond A. Myers** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**—** | Source of funds (See Instructions)<br>**—** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X1** | Citizenship or place of organization<br>**X1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**0.00** | Aggregate amount beneficially owned by each reporting person<br>**0.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**0%** | Percent of class represented by amount in Row (11)<br>**0%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

| **CUSIP No.** | **852312305** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Jason J. Martin** | Name of reporting person<br>**Jason J. Martin** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**—** | Source of funds (See Instructions)<br>**—** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X1** | Citizenship or place of organization<br>**X1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**0.00** | Aggregate amount beneficially owned by each reporting person<br>**0.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**0%** | Percent of class represented by amount in Row (11)<br>**0%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Stock, par value $0.01 per share

**(b) Name of Issuer:**
STAAR SURGICAL CO

**(c) Address of Issuer's Principal Executive Offices:**
25510 Commercentre Drive, Lake Forest, CA, 92630

This Amendment No. 43 to the Schedule 13D ("Amendment No. 43"), amends and supplements the statement on Schedule 13D filed with the U.S. Securities and Exchange Commission (the "SEC") on October 12, 2004, (the "Original Schedule 13D," as amended, the "Schedule 13D") with respect to shares of common stock, par value $0.01 per share (the "Shares") of STAAR Surgical Company (the "Issuer"). Capitalized terms used but not otherwise defined in this Amendment No. 43 have the meanings set forth in the Schedule 13D.

**Item 4. Purpose of Transaction**

Item 4 is hereby amended and supplemented by the addition of the following:

On January 14, 2026, Broadwood Partners entered into a letter agreement (the "Cooperation Agreement") with the Issuer.

Pursuant to the Cooperation Agreement, the Issuer agreed to (i) accept the resignations of Stephen C. Farrell and Elizabeth Yeu from the Board, (ii) increase the size of the Board from six to seven directors, (iii) appoint each of Neal C. Bradsher, Richard T. LeBuhn and Christopher Min Fang Wang to the Board and (iv) nominate each of Messrs. Bradsher, LeBuhn and Wang for election to the Board at the Issuer's 2026 annual meeting of stockholders (the "2026 Annual Meeting"). Additionally, Mr. Farrell is expected to remain CEO of the Issuer until January 31, 2026 or such earlier date as is determined by the Board. The Cooperation Agreement also provides that, until June 18, 2026, Broadwood Partners and its affiliates shall not, nor shall it encourage any other person to, request that the Company call a special meeting of stockholders for any reason, including, but not limited to, a special meeting to remove directors from the Board. Further, Broadwood Partners and the Issuer have agreed to release each other from any claims and customary mutual non-disparagement provisions.

The Issuer has also agreed to reimburse each of Broadwood Partners, Yunqi Capital and Defender Capital for reasonable and documented out-of-pocket fees and expenses incurred in connection with the Special Meeting for the Proposed Merger.

The foregoing description of the Cooperation Agreement does not purport to be complete and is qualified in it is entirety by reference to the full text of the Cooperation Agreement, which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

On January 14, 2026, each of Mr. Bradsher and Mr. LeBuhn were appointed as a director to the Board to serve until the 2026 Annual Meeting and until his respective successor is elected and qualified.

**Item 5. Interest in Securities of the Issuer**

**(a)**
Item 5 is hereby amended and supplemented by the addition of the following:

The aggregate percentage of Shares reported to be beneficially owned by the Reporting Persons is based upon 49,741,953 Shares outstanding as of October 31, 2025, as disclosed in the Issuer's Quarterly Report on Form 10-Q for the period ended September 26, 2025 filed with the SEC by the Issuer on November 5, 2025. As of the date hereof, Broadwood Partners may be deemed to beneficially own 15,453,629 Shares, representing approximately 31.1% of the Shares outstanding. As of the date hereof, Broadwood Capital may be deemed to beneficially own 15,453,629 Shares, representing approximately 31.1% of the Shares outstanding. As of the date hereof, Mr. Bradsher may be deemed to beneficially own 15,479,529 Shares, representing approximately 31.1% of the Shares outstanding.

**(b)**
Broadwood Partners has the sole power to vote or direct the vote of 0 Shares and the shared power to vote or direct the vote of 15,453,629 Shares. Broadwood Partners has sole power to dispose or direct the disposition of 0 Shares and the shared power to dispose or direct the disposition 15,453,629 Shares.

Broadwood Capital has the sole power to vote or direct the vote of 0 Shares and the shared power to vote or direct the vote of 15,453,629 Shares. Broadwood Capital has sole power to dispose or direct the disposition of 0 Shares and the shared power to dispose or direct the disposition 15,453,629 Shares.

Mr. Bradsher has the sole power to vote or direct the vote of 25,900 Shares and the shared power to vote or direct the vote of 15,453,629 Shares. Mr. Bradsher has sole power to dispose or direct the disposition of 25,900 Shares and the shared power to dispose or direct the disposition 15,453,629 Shares.

**(c)**
Each of Broadwood Capital and Messrs. Bradsher, LeBuhn, Capasso, Myers and Martin has not entered into any transactions during the past sixty days. The transactions in the Shares by Broadwood Partners during the past sixty days are set forth in Exhibit 99.2 and are incorporated herein by reference. All such transactions were effected in the open market through a broker.

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

Item 6 is hereby amended and supplemented by the addition of the following:

On January 14, 2026, Broadwood Partners and the Issuer entered into the Cooperation Agreement as described in Item 4 above and incorporated herein by reference.

Also on January 14, 2026, the Joint Filing and Solicitation Agreement terminated pursuant to its terms, effective immediately.

On January 16, 2026, the Reporting Persons entered into a Joint Filing Agreement (the "Joint Filing Agreement") in which the Reporting Persons agreed to the joint filing on behalf of each of them of statements on Schedule 13D, and any amendments thereto, with respect to securities of the Issuer to the extent required by law. The foregoing description of the Joint Filing Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Joint Filing Agreement, which is attached hereto as Exhibit 99.3 and is incorporated herein by reference.

As directors of the Issuer, each of Mr. Bradsher and Mr. LeBuhn is subject to and intends to comply with the policies and guidelines of the Issuer applicable to all directors of the Issuer, including, without limitation, policies related to the trading of the Issuer's securities.

As a result of each of Mr. Bradsher's and Mr. LeBuhn's positions at the Issuer, on the one hand, and Broadwood Partners and Broadwood Capital, on the other hand, Broadwood Partners and Broadwood Capital are subject to and intend to adhere to the policies of the Issuer, including certain policies related to the trading of the Issuer's securities, subject to certain exceptions.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Broadwood Partners, L.P.

**Signature:** /s/ Neal C. Bradsher

**Name/Title:** Neal C. Bradsher. President of Broadwood Capital, Inc.

**Date:** 01/16/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Broadwood Capital, Inc.

**Signature:** /s/ Neal C. Bradsher

**Name/Title:** Neal C. Bradsher, President

**Date:** 01/16/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Neal C. Bradsher

**Signature:** /s/ Neal C. Bradsher

**Name/Title:** Neal C. Bradsher

**Date:** 01/16/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Richard T. LeBuhn

**Signature:** /s/ Richard T. LeBuhn

**Name/Title:** Richard T. LeBuhn

**Date:** 01/16/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Natalie R. Capasso

**Signature:** /s/ Natalie R. Capasso

**Name/Title:** Natalie R. Capasso

**Date:** 01/16/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Raymond A. Myers

**Signature:** /s/ Raymond A. Myers

**Name/Title:** Raymond A. Myers

**Date:** 01/16/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Jason J. Martin

**Signature:** /s/ Jason J. Martin

**Name/Title:** Jason J. Martin

**Date:** 01/16/2026